Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
An ethical case describes the use of a virtual consultation with a pediatric psychiatrist when a 6-year-old boy seen in the emergency room has injuries suspected to be due to child abuse.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.